ITMCTR2000003796尚未招募1 期
A randomized, double-blind, placebo-controlled study of Jieyu Xifeng Decoction in the treatment of anxiety insomnia
Shanghai Hospital of traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 70（—）
- 性别
- All
入选标准
- •1. According to the diagnostic criteria of Western medicine for insomnia;
- •2. According to the TCM diagnostic criteria of insomnia;
- •3. The age is 18-70 years old;
- •4. PSQI score > 11, Spiegel Sleep Scale (improved) score > 12,HAMA score >= 14, and HAMA < 30;
- •5. No traditional Chinese medicine or western medicine was used to treat insomnia symptoms in the past month, or other drugs were taken in a short time (1 week), but no effect was found;
- •6. Those who voluntarily participate in this clinical study, are willing to receive treatment in accordance with the prescribed course of treatment, and can sign informed consent.
排除标准
- •1. Patients with depression, severe anxiety, bipolar disorder, schizophrenia, aphasia and other serious, neuropsychiatric diseases, accompanied by thyroid function, hypertension, coronary heart disease and with serious heart, liver, kidney or other serious organic damage disease;
- •2. Pregnant and lactating women;
- •3. Subjects taking sleeping pills, antidepressants, etc.;
- •4. Those who fail to treat according to the specified requirements, and fill in incomplete information, etc. can not accurately judge the curative effect.
研究者
相似试验
未知
3 期
A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF-alpha agentsRheumatoid ArthritisJPRN-jRCT2080221561ovartis Pharma K.K.
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia - RESTORETS (lower urinary tract symptoms) associated with BPH (benign prostatic hyperplasia)EUCTR2005-001627-11-PTYamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)1,051
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasiaEUCTR2005-001627-11-ITYAMANOUCHI PHARMA882
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia - RESTOREEUCTR2005-001627-11-FIYamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)1,051
进行中（未招募）
1 期
Evaluation of Efficacy and Safety of Sarilumab in Patients with GCAMedDRA version: 20.0Level: LLTClassification code 10018250Term: Giant cell arteritisSystem Organ Class: 100000004866Giant Cell ArteritisEUCTR2017-002988-18-BESanofi-Aventis Recherche & Développement508